**Name of journal: World Journal of Radiology**

**ESPS Manuscript NO: 7946**

**Columns:** **REVIEW**

Radiation pneumonitis after stereotactic radiation therapy for lung cancer

Yamashita H *et al.* RP after SBRT for lung cancer

Hideomi Yamashita, Wataru Takahashi, Akihiro Haga, Keiichi Nakagawa

**Hideomi Yamashita, Wataru Takahashi, Akihiro Haga, Keiichi Nakagawa,** Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan

**Author contributions:** Yamashita H designed the study and performed the majority of work, including literature review and writing the first draft of the manuscript; Takahashi W, Haga A and Nakagawa K provided advice regarding important intellectual content of the topical discussion.

**Correspondence to: Hideomi Yamashita, MD, PhD,** Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. [yamachan07291973@yahoo.co.jp](mailto:yamachan07291973@yahoo.co.jp)

**Telephone**: +81-3-58008667 **Fax:** +81-3-58008935

**Received:** December 7, 2013 **Revised:** July 1, 2014

**Accepted:** July 15, 2014

**Published online:**

**Abstract**

Stereotactic body radiation therapy (SBRT) has a local control rate of 95% at 2 years for non-small cell lung cancer (NSCLC) and should improve the prognosis of inoperable patients, elderly patients, and patients with significant comorbidities who have early-stage NSCLC. The safety of SBRT is being confirmed in international, multi-institutional Phase II trials for peripheral lung cancer in both inoperable and operable patients, but reports so far have found that SBRT is a safe and effective treatment for early-stage NSCLC and early metastatic lung cancer. Radiation pneumonitis (RP) is one of the most common toxicities of SBRT. Although most post-treatment RP is Grade 1 or 2 and either asymptomatic or manageable, a few cases are severe, symptomatic, and there is a risk for mortality. The reported rates of symptomatic RP after SBRT range from 9% to 28%. Being able to predict the risk of RP after SBRT is extremely useful in treatment planning. A dose-effect relationship has been demonstrated, but suggested dose-volume factors like mean lung dose, lung V20, and/or lung V2.5 differed among the reports. We found that patients who present with an interstitial pneumonitis shadow on computed tomography scan and high levels of serum Krebs von den Lungen-6 and surfactant protein D have a high rate of severe radiation pneumonitis after SBRT. At our institution, lung cancer patients with these risk factors have not received SBRT since 2006, and our rate of severe RP after SBRT has decreased significantly since then.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Radiation pneumonitis; Stereotactic radiation therapy; Dose-volume factors; Krebs von den Lungen-6; Surfactant protein D; Computed tomography changes

**Core tip:** Radiation pneumonitis (RP) is one of the most common toxicities after stereotactic body radiation therapy (SBRT). Although most RP is Grade 1 or 2 and either asymptomatic or manageable, a few cases are severe and there is a risk for mortality. A dose-effect relationship has been demonstrated that can be used for treatment planning. Other prognostic indicators of severe radiation pneumonitis after SBRT are an interstitial pneumonitis shadow on computed tomography scan and high levels of serum Krebs von den Lungen-6 (KL-6) and surfactant protein D before treatment.

Yamashita H, Takahashi W, Haga A, Nakagawa K. Radiation pneumonitis after stereotactic radiation therapy for lung cancer.*World J Radiol*2014; In press

**INTRODUCTION**

Stereotactic body radiotherapy (SBRT) is becoming standard of care therapy for patients with inoperable early-stage non-small cell peripheral lung cancer or lung cancer with limited demarcated metastases. The delivery of higher doses to smaller lung planning target volumes (PTVs) limits toxicity in the normal lung tissue surrounding the tumor to very limited areas. Local control of up to 95% at 2 years has been reported[1-4].

Given the improved local control and toxicity results reported by recent lung SBRT studies[1-4], future directions for this technique include the treatment of larger lesions. Palma *et al*[5] and Diot *et al*[6] suggest that toxicity might increase with lesion size, and this possibility should be anticipated and closely monitored.

Symptomatic lung toxicity with SBRT is typically less than 10%[7]; however, occurrences up to 25% have been reported[8], highlighting the necessity of developing SBRT treatment parameters that ensure consistently low toxicity levels.

Radiation-induced pneumonitis is the most frequent acute pulmonary toxicity. The majority of patients develop asymptomatic Grade 1 pneumonitis. Clinically symptomatic pneumonitis develops in less than 10% of patients, but most patients develop late pulmonary toxicity characterized by localized pulmonary fibrosis in the high-dose region[11]. Because this fibrosis is usually asymptomatic, we considered post-SBRT pulmonary function changes the clinically relevant endpoint of our review.

A dose-effect relationship has been demonstrated for SBRT that is similar to that observed in conventionally fractionated radiation therapy[9-10]; but a study by Guckenberger *et al*[12] failed to demonstrate this relationship in early-stage non-small cell lung cancer. Gluckenberger’s results were based on a large number of patients[12] and confirmed the findings in other studies that post-SBRT pulmonary function was either stable[13-17] or almost asymptomatic[18-19]. These data were encouraging and further supported the safety of SBRT.

SBRT has been widely used as a safe and effective treatment for primary or metastatic lung tumors for a number of years[20]. According to the protocol of the Japan Clinical Oncology Group (JCOG) 0403 study[21-22], the only absolute contraindication to SBRT is pregnancy.

In Japan, medical service fees officially cover SBRT treatment for primary and metastatic lung cancers only if the tumor is under 5 cm in size, there are no more than three tumors, and there is no metastatic disease in other organs. In Japan, surgery is generally the first-line treatment for early primary lung cancer, so primary lung cancer patients who undergo SBRT are in poor condition and either have multiple primary cancers or co-morbidities such as serious cardiovascular disease. Most Japanese patients with primary lung tumors who received SBRT had low pulmonary function from chronic obstructive pulmonary disease due to long smoking histories.

Contraindications to SBRT were (1) a history of irradiation to the concerned site; (2) severe interstitial pneumonitis or pulmonary fibrosis; (3) severe diabetes or connective tissue disease; and (4) common use of steroids.

**LOCAL CONTROL RATE OF SBRT**

SBRT with 3D conformal or intensity-modulation techniques is an effective treatment for localized early-stage lung cancer, with local control rates of 85.5% to 100% 2 to 3 years following treatment[1-4]. SBRT is also being employed to treat metastatic lung cancer, although the survival rates are not comparable to those for early-stage (T1 – T2, N0) disease[2].

The excellent local control rates for early-stage lung cancer treated with SBRT are leading to extensive use of this technique in clinical practice and to randomized trials comparing surgery to SBRT for Stage I non-small cell lung cancers in operable patients. Two randomized trials to compare SBRT to surgery for operable patients with Stage I lung cancer were launched in 2008: one in the Netherlands [the Randomized Clinical Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer (ROSEL) trial] and one in the United States (testing the Cyberknife by Accuray Inc., Sunnyvale, CA, United States).

**PREVIOUS REPORTS OF TOXICITIES AFTER SBRT**

The safety of SBRT is being confirmed in multi-institutional Phase II trials for peripheral lung cancer in both inoperable[16, 23] and operable patients[22]. In the Radiation Therapy Oncology Group (RTOG) trial 0236[23], protocol-specific, treatment-related Grade 3 and 4 adverse events occurred in 12.7% (7/59) and 3.6% (2/59) of cases, respectively. No Grade 5 adverse events were reported. In the Nordic Phase II study of SBRT[16]. Grade 3 toxicities were seen in 21% (12/57) of cases, but no Grade 4 or 5 toxicities were reported. Nishio *et al*[22]reported Grade 3 toxicities in 6.2% of operable patients in the JCOG 0403 trial.

Severe clinical toxicities after SBRT are fairly uncommon and occur more frequently in cases of centrally located tumors, such as those near the trachea, primary bronchus, major blood vessels and pericardium[3]. Rates of serious toxicities are low in most studies. Previous reports have described skin, chest wall, and brachial plexus toxicities with their associated risk factors[24-27].

This review documents clinically significant radiation pneumonitis (RP) rates for medically inoperable non-small cell lung cancer (NSCLC) patients treated with SBRT, adding to the sparse literature on pulmonary toxicity resulting from hypo-fractionated radiotherapy.

**RP AFTER SBRT**

RP is one of the most common toxicities after SBRT, as well as after conventional radiotherapy to the lung. Scoring systems should be considered when interpreting RP results. The reported rates of symptomatic RP after SBRT range from 9% to 28%[8-10, 28-31]. Although most of the RP was Grade 1 or 2 and either asymptomatic or manageable, a few cases were severe and there was a risk for mortality[8]. It is very important to develop a method to predict the risk of RP after SBRT for lung cancer.

Grade 3 RP was observed in 3.6% of the overall patients in RTOG 0236[23] and in 3.1% of the operable patients in JCOG 0403[22]. Baumann *et al*[16] reported that no one developed Grade 3 pneumonitis in their Phase II trial of SBRT.

McGarry *et al*[31] reported that 2% (1/47) of patients developed circulating tumor cells (CTCs) and 6.4% (3/47) of patients developed Grade 2 and 3 RP in the updated Indiana University Phase I trial that included tumors up to 7 cm in size plus central lesions. G2 toxicity occurred at a dose of 48 Gy, and G3 toxicities developed after 54 Gy and 72 Gy in 3 fractions prescribed to the 80% iso-dose line[33]. Using similar criteria, Onishi reported 4.1% G2 (10/245), 1.2% G3 (3/245), and 1.2% G4 (3/245) RP in a multi-institutional trial of SBRT in Japan[32]. Nagata and colleagues reported no G3 or G4 RP using a slightly less potent dose of 48 Gy in 4 fractions delivered to the iso-center[1].

In the RTOG, Ricardi *et al*[33] treated 62 patients to 45 Gy in 3 fractions to the 80% iso-dose line and reported a 3.2% incidence of Grade 3 RP that required steroids or intermittent oxygen. When Stephans *et al*[34] treated (*n* = 56) patients to 50 Gy in 5 fractions and (*n* = 38) patients to 60 Gy in 3 fractions, there was a 2.3% incidence of RP that required steroids (for all 94 patients).

Grills *et al*[35] recently published a case–control study comparing SBRT to wedge resection. In that report, there was 11% G2 - 3 RP using a CTC *vs* a grading system based on the Common Terminology of Criteria of Adverse Events. Only 2% of these patients required temporary steroids for management. Finally, G3 RP occurred at a rate of 3.6% (2/55) in RTOG 0236[23].

Although the reported toxicities of lung SBRT have, for the most part, been minor, the dose constraints to use during treatment planning are based on extremely limited clinical data, most of which has not been validated[36]. Even the recent QUANTEC lung article devoted only one paragraph to the risk of pneumonitis in lung SBRT patients[7]. Baker *et al*[37] reported in QUANTEC that the greatest incidence of pneumonitis was Grade 1 (64.2%) (169/263), and there were 26 cases (9.9%) of Grade 2 pneumonitis and 3 cases (1.1%) of Grade 3 pneumonitis.

**DOSE-VOLUME FACTORS FOR RP AFTER SBRT**

Table 1 summarizes published reports that focused on the dose volumetrics associated with Grade 2 RP or worse after SBRT. The RP rates varied from 9.4% to 28.0%, and the suggested dose-volume factors for RP differed among the reports. This variation might be caused by differences in the PTV volume, dose fractionation schedule, or RP scoring system.

Since most patients with pulmonary metastases had residual or recurrent disease after first-line treatment with chemotherapy, it appeared appropriate to consider a V20 of 30% as the dose restriction in SBRT for metastatic lung cancer.

Borst *et al*[10] evaluated the relationship between the mean lung dose (MLD) and the incidence of RP after SBRT. They calculated the MLD in the normalized total dose form, using the linear-quadratic model with a α/β ratio of 3. A significant dose-response relationship was found between RP and MLD.

According to Baker *et al*[10], the data from their center and the Japanese group demonstrate that a V20 of less than 10% is readily achievable, and at those levels pneumonitis is not statistically predictable. Analogously, an MLD of approximately 5 - 6 Gy is achievable, and at this dosage pneumonitis should not develop. Therefore, dosimetric guidelines of a V20 of less than 10% and an MLD of less than 6 Gy are a reasonable way to reduce the occurrence of Grades 2 - 4 RP. A German article suggested that a higher MLD or higher V2.5 - V50 (V2.5 in particular) was associated with symptomatic RP[9].

The Mayo Clinic recently reported on a series of patients treated at their institution with consecutive daily fractions of SBRT[32]. There was a 12.5% overall incidence of Grade 2 pneumonitis, but a 14.3% incidence in patients treated either with 54 Gy in three fractions for peripheral lesions or 48 Gy in four fractions for central lesions. In a univariate analysis, a PTV maximum dose greater than 60 Gy was predictive of RP (*P* = 0.016), although the overall number of events was small (*n* = 4). No other factors were statistically significant[32]. The decline in pulmonary function seemed to be transient, similar to the initial experience at Indiana University[38].

It is unclear exactly how RP correlates with changes in pulmonary function testing. This is an area that requires further research. It is interesting to note, however, that a dose of radiation higher than V10 was predictive of RP in the Indiana University patients, at least on univariate analysis. The same findings were reported by the Cleveland Clinic[34]. The conformity index was not predictive under univariate or multivariate modeling.

At our institution, we suppress the patient’s respiration during SBRT using abdominal compression in order to reduce lung V20 and MLD[8,39]. We had used irradiation dose of 48 Gy in 4 fractions (Figure 1). We also used 4D cone beam computed tomography (CT) to evaluate internal target volume and tumor motion just before SBRT, with the result that the margin between the internal target volume and the PTV became narrower[40,41].

**EXPRESSSION OF KREBS VON DEN LUNGEN-6 IS A PREDICTOR OF RP AFTER SBRT**

High levels of the glycoprotein Krebs von den Lungen-6 (KL-6) indicate interstitial pneumonitis (IP), and the levels rise significantly with physical activity in IP cases. In the human body, KL-6 only develops in type II alveolus epithelial cells, bronchial epithelial cells, and bronchus gland cells. A small quantity of KL-6 is present in the liquid coating the alveoli in normal lungs, but it occurs in higher levels in hyperplastic type II alveolus epithelial cells when IP is present. Inflammation also occurs in IP, which increases the permeability of the blood vessels and allows KL-6 to move into the blood where it can be measured. Blood levels of KL-6, surfactant protein D (SP-D), surfactant protein A (SP-A), and monocyte chemoattractant protein-1 (MCP-1) are evaluated whenever there is an injury to the lung stroma, and KL-6 is the most sensitive (93.9%) and specific (96.3%) of these measures where the detection of RP is concerned[42]. SP-D levels at 50 to 60 Gy (midway through radiation therapy) showed greater sensitivity and positive predictive values for RP detection (74% and 68%, respectively) than SP-A (26% and 21%, respectively)[ 43].

Factors other than dose volumetrics also affect the incidence of pneumonitis after SBRT. Hara *et al*[44] evaluated 16 patients who received single-fraction SBRT from 20 to 35 Gy. Serum KL-6 levels rose significantly between pretreatment presentation and two months after SBRT was administered, and it was significantly correlated with Grade 3 RP by the RTOG criteria.

Iwata *et al*[45]reported that pretreatment serum KL-6 levels, gender, and PTV volume were associated with symptomatic RP in a univariate analysis, and pretreatment KL-6 levels remained significant in a multivariate analysis. They concluded that patients with pretreatment KL-6 levels ≥ 300 /ml should be followed carefully for RP. CT or X-ray imaging of the lung before and after SBRT should also help to predict severe RP.

To limit the risk of severe RP, werecommended to everyone prescreening for interstitial pneumonitis with CT scans and checking serum KL-6 and SP-D levels. After introducing these measures, we reported that the incidence of Grade 4 and 5 RP decreased from 18.8% to 3.5%[45].

Takeda *et al*[46] reported that the sooner RP appeared on chest x-ray after SBRT was administered, the more severe it was. The radiographic appearance of RP during the initial 2 mo after SBRT indicated a 40% risk for Grade 3 RP. The risk was only 1.2% when radiologic changes appeared 3 mo after SBRT.

Evaluating KL-6 and SP-D levels, radiologic imaging before and after treatment, and adjusting dose-volume factors during treatment planning helps lower the risk of severe pneumonitis after SBRT. While the biomarkers are both sensitive and specific for RP, the pathophysiological mechanisms underlying their predictive value are unclear, which makes some clinicians hesitate to use them.

At our institution, Grades 4 and 5 RP occurred in 6 out of 32 patients (18.8%) who received SBRT treatment for lung cancer before 2005 and only 3 out of 85 patients (3.5%) between 2006 and 2013[8,39]. We believe that the significant reduction in the occurrence of Grades 4 - 5 RP is due to our use of prognostic biomarkers and radiography to select appropriate patients for SBRT treatment. After 2006, patients were excluded from SBRT if they had an obvious IP shadow on their CT scan (slice thickness 3.0 mm), and/or if serum KL-6 and SP-D levels were high[**39**].

**RP AFTER SBRT FOR METASTATIC LUNG CANCER**

SBRT is also used to treat pulmonary metastases in selected patients and treatment results seem comparable to those obtained by surgical metastasectomy[47]. In this setting, the literature reports that Grade 3 RP occurred in 3% to 5% of cases[2,47,48]. According to Inoue[48], the incidence of G3/4 adverse respiratory events after SBRT for pulmonary metastases was 10%.

**GENE EXPRESSION CLASSIFIER**

It was reported that radiation pneumonitis after SBRT treatment for lung cancer was associated with pro-inflammatory genes such as TGFB1 or CD44. Accumulating the number of cases appropriate for statistically significant gene analysis might be difficult, and there is no information about predisposing genetic risk factors for lung cancer.

Yuan *et al*[49] reported in 2009 that he and his colleagues at the M.D. Anderson Cancer Center in Houston, Texas, USA, performed an association analysis between pneumonitis onset risk in both Black and White patients who received radiotherapy and/or chemotherapy for NSCLC (94% in both cases). The polymorphism marker on the THFB1 and T869C genes was associated with a low risk of developing RP or IP.

In recent years, many studies have found that SBRT for early stage lung cancer is both effective and safe[1, 50], but there are only a few reports about the development of dangerous and lethal radiation pneumonitis that can result from SBRT[8], or the pulmonary fibrosis that may also appear[50].

**A TIMELINE AND PATTERN OF CT CHANGES**

There have been few studies on CT findings in radiation-induced lung disease after SBRT for lung cancer[50]. Due to the differences in dose delivery and distribution, biologic effects, and overall treatment time, it is reasonable to expect that any CT changes that occur after SBRT will not have the same appearance, geographic extent, and progression timeline as those following CRT for lung cancers[51].

Like CRT-induced CT changes, CT findings after SBRT have two stages: early acute radiation pneumonitis that occurs within 6 months of treatment and radiation fibrosis that occurs 6 months or more after treatment[51,52]. In most cases, radiologic changes in normal lung tissue do not occur until at least 3 mo after SBRT. Clinical symptoms of acute radiation-induced lung injury develop approximately 3 to 6 mo after treatment. All of the severe RP cases in our institution consisted of the acute exacerbation of IP that was spread out over the radiation field (Figure 2)[ 39].

The analysis of SBRT-induced normal lung density changes by Diot *et al*[6] indicates that self-limiting acute effects in normal lung tissue are more pronounced than late effects, and acute CT changes in patients treated with 3 fractions were considerably less than those in patients treated with 4 or 5 fractions. The changes seemed to be explained by either increased low-dose exposure in normal lung tissue or differences in tumor volume.

**CONCLUSION**

On the basis of this review, radiation-induced pneumonitis is the most frequent acute pulmonary toxicity following SBRT for lung cancer. The majority of patients develop asymptomatic Grade 1 or asymptomatic and/or manageable Grade 2 pneumonitis, and clinically symptomatic pneumonitis is observed in less than 10%. A dose-effect relationship has been demonstrated that is useful in treatment planning. Since patients with an IP shadow on CT scan and high levels of serum KL-6 and SP-D before SBRT treatment develop severe radiation pneumonitis at a high rate after treatment, they should not receive SBRT.

**REFERENCES**

1 **Nagata Y**, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. *Int J Radiat Oncol Biol Phys* 2005; **63**: 1427-1431 [PMID: 16169670]

2 **Rusthoven KE**, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. *J Clin Oncol* 2009; **27**: 1579-1584 [PMID: 19255320 DOI: 10.1200/JCO.2008.19.6386]

3 **Timmerman R**, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. *J Clin Oncol* 2006; **24**: 4833-4839 [PMID: 17050868]

4 **Xia T**, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2006; **66**: 117-125 [PMID: 16765528]

5 **Palma DA**, van Sörnsen de Koste J, Verbakel WF, Vincent A, Senan S. Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. *Int J Radiat Oncol Biol Phys* 2011; **81**: 974-978 [PMID: 20932655 DOI: 10.1016/j.ijrobp.2010.07.025]

6 **Diot Q**, Kavanagh B, Schefter T, Gaspar L, Stuhr K, Miften M. Regional normal lung tissue density changes in patients treated with stereotactic body radiation therapy for lung tumors. *Int J Radiat Oncol Biol Phys* 2012; **84**: 1024-1030 [PMID: 22583607 DOI: 10.1016/j.ijrobp.2011.11.080]

7 **Marks LB**, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, Martel MK, Jackson A. Radiation dose-volume effects in the lung. *Int J Radiat Oncol Biol Phys* 2010; **76**: S70-S76 [PMID: 20171521 DOI: 10.1016/j.ijrobp.2009.06.091]

8 **Yamashita H**, Nakagawa K, Nakamura N, Koyanagi H, Tago M, Igaki H, Shiraishi K, Sasano N, Ohtomo K. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. *Radiat Oncol* 2007; **2**: 21 [PMID: 17553175]

9 **Guckenberger M**, Baier K, Polat B, Richter A, Krieger T, Wilbert J, Mueller G, Flentje M. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. *Radiother Oncol* 2010; **97**: 65-70 [PMID: 20605245 DOI: 10.1016/j.radonc.2010.04.027]

10 **Borst GR**, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Onimaru R, van den Heuvel MM, Belderbos J, Lebesque JV, Sonke JJ. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. *Radiother Oncol* 2009; **91**: 307-313 [PMID: 19321217 DOI: 10.1016/j.radonc.2009.02.003]

11 **Huang K**, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, Boldt RG, Palma DA. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. *Radiother Oncol* 2012; **102**: 335-342 [PMID: 22305958 DOI: 10.1016/j.radonc.2011.12.018]

12 **Guckenberger M**, Klement RJ, Kestin LL, Hope AJ, Belderbos J, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Xiao Y, Grills IS. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2013; **85**: 1074-1081 [PMID: 23154077 DOI: 10.1016/j.ijrobp.2012.09.016]

13 **Stephans KL**, Djemil T, Reddy CA, Gajdos SM, Kolar M, Machuzak M, Mazzone P, Videtic GM. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. *J Thorac Oncol* 2009; **4**: 838-844 [PMID: 19487961 DOI: 10.1097/JTO.0b013e3181a99ff6]

14 **Bral S**, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B, Verdries D, Everaert H, Christian N, De Ridder M, Storme G. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. *Int J Radiat Oncol Biol Phys* 2011; **80**: 1343-1349 [PMID: 20708849 DOI: 10.1016/j.ijrobp.2010.04.056]

15 **Fritz P**, Kraus HJ, Blaschke T, Mühlnickel W, Strauch K, Engel-Riedel W, Chemaissani A, Stoelben E. Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. *Lung Cancer* 2008; **60**: 193-199 [PMID: 18045732]

16 **Baumann P**, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JS, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. *Radiother Oncol* 2008; **88**: 359-367 [PMID: 18768228 DOI: 10.1016/j.radonc.2008.07.019]

17 **Ohashi T**, Takeda A, Shigematsu N, Kunieda E, Ishizaka A, Fukada J, Deloar HM, Kawaguchi O, Takeda T, Takemasa K, Isobe K, Kubo A. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. *Int J Radiat Oncol Biol Phys* 2005; **62**: 1003-1008 [PMID: 15990001]

18 **Henderson M**, McGarry R, Yiannoutsos C, Fakiris A, Hoopes D, Williams M, Timmerman R. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2008; **72**: 404-409 [PMID: 18394819 DOI: 10.1016/j.ijrobp.2007.12.051]

19 **Miyamoto T**, Baba M, Yamamoto N, Koto M, Sugawara T, Yashiro T, Kadono K, Ezawa H, Tsujii H, Mizoe JE, Yoshikawa K, Kandatsu S, Fujisawa T. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. *Int J Radiat Oncol Biol Phys* 2007; **67**: 750-758 [PMID: 17293232]

20 **Nagata Y**, Negoro Y, Aoki T, Mizowaki T, Takayama K, Kokubo M, Araki N, Mitsumori M, Sasai K, Shibamoto Y, Koga S, Yano S, Hiraoka M. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. *Int J Radiat Oncol Biol Phys* 2002; **52**: 1041-1046 [PMID: 11958900]

21 **Matsuo Y**, Takayama K, Nagata Y, Kunieda E, Tateoka K, Ishizuka N, Mizowaki T, Norihisa Y, Sakamoto M, Narita Y, Ishikura S, Hiraoka M. Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. *Int J Radiat Oncol Biol Phys* 2007; **68**: 416-425 [PMID: 17363190]

22 **Nishio T**, Kunieda E, Shirato H, Ishikura S, Onishi H, Tateoka K, Hiraoka M, Narita Y, Ikeda M, Goka T. Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403). *Phys Med Biol* 2006; **51**: 5409-5417 [PMID: 17047260]

23 **Timmerman R**, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. *JAMA* 2010; **303**: 1070-1076 [PMID: 20233825 DOI: 10.1001/jama.2010.261]

24 **Andolino DL**, Forquer JA, Henderson MA, Barriger RB, Shapiro RH, Brabham JG, Johnstone PA, Cardenes HR, Fakiris AJ. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. *Int J Radiat Oncol Biol Phys* 2011; **80**: 692-697 [PMID: 21288656 DOI: 10.1016/j.ijrobp.2010.03.020]

25 **Dunlap NE**, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter TE, Kavanagh BD, Larner JM. Chest wall volume receiving & gt; 30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. *Int J Radiat Oncol Biol Phys* 2010; **76**: 796-801 [PMID: 19427740 DOI: 10.1016/j.ijrobp.2009.02.027]

26 **Hoppe BS**, Laser B, Kowalski AV, Fontenla SC, Pena-Greenberg E, Yorke ED, Lovelock DM, Hunt MA, Rosenzweig KE. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? *Int J Radiat Oncol Biol Phys* 2008; **72**: 1283-1286 [PMID: 19028267 DOI: 10.1016/j.ijrobp.2008.08.036]

27 **Ricardi U**, Filippi AR, Guarneri A, Giglioli FR, Mantovani C, Fiandra C, Anglesio S, Ragona R. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. *Acta Oncol* 2009; **48**: 571-577 [PMID: 19031164 DOI: 10.1080/02841860802520821]

28 **Ong CL**, Palma D, Verbakel WF, Slotman BJ, Senan S. Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. *Radiother Oncol* 2010; **97**: 431-436 [PMID: 20971523 DOI: 10.1016/j.radonc.2010.10.003]

29 **Barriger RB**, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PA, Fakiris AJ. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys* 2012; **82**: 457-462 [PMID: 21035956 DOI: 10.1016/j.ijrobp.2010.08.056]

30 **Stauder MC**, Macdonald OK, Olivier KR, Call JA, Lafata K, Mayo CS, Miller RC, Brown PD, Bauer HJ, Garces YI. Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. *Radiother Oncol* 2011; **99**: 166-171 [PMID: 21571384 DOI: 10.1016/j.radonc.2011.04.002]

31 **McGarry RC**, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. *Int J Radiat Oncol Biol Phys* 2005; **63**: 1010-1015 [PMID: 16115740]

32 **Onishi H**, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. *Cancer* 2004; **101**: 1623-1631 [PMID: 15378503]

33 **Ricardi U**, Filippi AR, Guarneri A, Giglioli FR, Ciammella P, Franco P, Mantovani C, Borasio P, Scagliotti GV, Ragona R. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. *Lung Cancer* 2010; **68**: 72-77 [PMID: 19556022 DOI: 10.1016/j.lungcan.2009.05.007]

34 **Stephans KL**, Djemil T, Reddy CA, Gajdos SM, Kolar M, Mason D, Murthy S, Rice TW, Mazzone P, Machuzak M, Mekhail T, Videtic GM. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. *J Thorac Oncol* 2009; **4**: 976-982 [PMID: 19633473 DOI: 10.1097/JTO.0b013e3181adf509]

35 **Grills IS**, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, Wloch J, Ye H, Kestin LL. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. *J Clin Oncol* 2010; **28**: 928-935 [PMID: 20065181 DOI: 10.1200/JCO.2009.25.0928]

36 **Timmerman RD**. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. *Semin Radiat Oncol* 2008; **18**: 215-222 [PMID: 18725106 DOI: 10.1016/j.semradonc.2008.04.001]

37 **Baker R**, Han G, Sarangkasiri S, DeMarco M, Turke C, Stevens CW, Dilling TJ. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. *Int J Radiat Oncol Biol Phys* 2013; **85**: 190-195 [PMID: 22929858 DOI: 10.1016/j.ijrobp.2012.03.041]

38 **Timmerman R**, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, Williams M. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. *Chest* 2003; **124**: 1946-1955 [PMID: 14605072]

39 **Yamashita H**, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, Ohtomo K, Nakagawa K. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. *Radiat Oncol* 2010; **5**: 32 [PMID: 20459699 DOI: 10.1186/1748-717X-5-32]

40 **Takahashi W**, Yamashita H, Kida S, Masutani Y, Sakumi A, Ohtomo K, Nakagawa K, Haga A. Verification of planning target volume settings in volumetric modulated arc therapy for stereotactic body radiation therapy by using in-treatment 4-dimensional cone beam computed tomography. *Int J Radiat Oncol Biol Phys* 2013; **86**: 426-431 [PMID: 23562767 DOI: 10.1016/j.ijrobp.2013.02.019]

41 **Nakagawa K**, Haga A, Kida S, Masutani Y, Yamashita H, Takahashi W, Sakumi A, Saotome N, Shiraki T, Ohtomo K, Iwai Y, Yoda K. 4D registration and 4D verification of lung tumor position for stereotactic volumetric modulated arc therapy using respiratory-correlated cone-beam CT. *J Radiat Res* 2013; **54**: 152-156 [PMID: 22843380 DOI: 10.1093/jrr/rrs058]

42 **Ohnishi H**, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. *Am J Respir Crit Care Med* 2002; **165**: 378-381 [PMID: 11818324]

43 **Kong FM**, Ao X, Wang L, Lawrence TS. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. *Cancer Control* 2008; **15**: 140-150 [PMID: 18376381]

44 **Hara R**, Itami J, Komiyama T, Katoh D, Kondo T. Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. *Chest* 2004; **125**: 340-344 [PMID: 14718465]

45 **Iwata H**, Shibamoto Y, Baba F, Sugie C, Ogino H, Murata R, Yanagi T, Otsuka S, Kosaki K, Murai T, Miyakawa A. Correlation between the serum KL-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage I lung cancer or small lung metastasis. *Radiother Oncol* 2011; **101**: 267-270 [PMID: 21640420 DOI: 10.1016/j.radonc.2011.05.031]

46 **Takeda A**, Ohashi T, Kunieda E, Enomoto T, Sanuki N, Takeda T, Shigematsu N. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. *Int J Radiat Oncol Biol Phys* 2010; **77**: 685-690 [PMID: 20510193 DOI: 10.1016/j.ijrobp.2009.06.001]

47 **Hof H**, Hoess A, Oetzel D, Debus J, Herfarth K. Stereotactic single-dose radiotherapy of lung metastases. *Strahlenther Onkol* 2007; **183**: 673-678 [PMID: 18040611]

48 **Norihisa Y**, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, Mizowaki T, Yano S, Hiraoka M. Stereotactic body radiotherapy for oligometastatic lung tumors. *Int J Radiat Oncol Biol Phys* 2008; **72**: 398-403 [PMID: 18374506 DOI: 10.1016/j.ijrobp.2008.01.002]

49 **Yuan X**, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, Milas L, Wei Q. Single nucleotide polymorphism at rs1982073: T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. *J Clin Oncol* 2009; **27**: 3370-3378 [PMID: 19380441 DOI: 10.1200/JCO.2008.20.6763]

50 **Takeda A**, Enomoto T, Sanuki N, Nakajima T, Takeda T, Sayama K, Kunieda E. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. *Radiat Med* 2008; **26**: 504-507 [PMID: 18975053 DOI: 10.1007/s11604-008-0261-8]


51 **Guckenberger M**, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. *Radiother Oncol* 2007; **85**: 435-442 [PMID: 18053602]

52 **Kimura T**, Matsuura K, Murakami Y, Hashimoto Y, Kenjo M, Kaneyasu Y, Wadasaki K, Hirokawa Y, Ito K, Okawa M. CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? *Int J Radiat Oncol Biol Phys* 2006; **66**: 483-491 [PMID: 16904838]

53 **Matsuo Y**, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, Miyagi K, Norihisa Y, Mizowaki T, Nagata Y, Hiraoka M. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. *Int J Radiat Oncol Biol Phys* 2012; **83**: e545-e549 [PMID: 22436782 DOI: 10.1016/j.ijrobp.2012.01.018]

**P-Reviewers:** Can MM, Storto G, Sun Z **S-Editor:** Wen LL

**L-Editor: E-Editor:**

****


**Figure 1 Dose distribution of stereotactic body radiation therapy of 48 Gy in 4 fractions.**

****

A

****

B

****

C

**Figure 2 Computed tomography image.** A: Before stereotactic body radiation therapy (SBRT) but after surgery for a left lung cancer. The nodule in the lower lobe of the right lung (S6) increased to 23 mm; B: Taken at post-SBRT month 5; C: Taken at post-SBRT month 7. Acute exacerbation of interstitial pneumonitis was found.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1** **Summary of reports on Grade 2 radiation pneumonitis after stereotactic body radiation therapy** | | | | | | | | | | | | |
| **First author** | **Ref.** | **Year** | **Gy** | **Pt no.** | **Median PTV, cc** | **Median follow-up in months** | **G2- RP** | **G3 RP** | **G4 RP** | **G5 RP** | **RP factor 1** | **RP factor 2** |
| Onishi | [32] | 2004 | 18-75Gy/1-25Fr | 245 | NA | 24 | 6.5% | 1.2% | 1.2% | 0% |  |  |
| McGarry | [31] | 2005 | 24Gy/  3Fr | 47 | NA | NA | 8.4% | 4.3% | 2.1% | 0% |  |  |
| Takahashi | [40] | 2006 | 15-30Gy | 32 | NA | 18 | 12.5% |  | 0% | 6% |  |  |
| Yamashita | [8] | 2007 | 48Gy/  4-6Fr | 25 | 43.9 | 17 | 28.0% | 4% | 4% | 12% | CI |  |
| Baumann | [16] | 2008 | 45Gy/  3Fr | 60 | NA | 23 | NA | 21% | 0% | 0% |  |  |
| Ricardi | [27] | 2009 | 45Gy/  3Fr  or  26Gy/  1Fr | 60 | NA | 30.9 | 14.3% | 3.2% | 0% | 0% | MLD |  |
| Borst | [10] | 2009 | 35-60Gy/4-8Fr | 128 | 9.6 | 16.1 | 10.9% | 0.8% | 0% | 0% | MLD |  |
| Stephans | [13] | 2009 | 60Gy/  3Fr  or 50Gy/  5Fr | 86 | 39.9/  30.4 | 15.3 | 2.3% | 0% | 0% | 0% |  |  |
| Rusthoven | [2] | 2009 | 48-60Gy/3Fr | 7 | NA | 15.4 | 2.6% |  |  |  |  |  |
| Yamashita | [39] | 2010 | 48Gy/  4Fr | 117 | NA | 14.7 | NA | 1.7% | 1.7% | 6.0% | KL-6 & SP-D | IP-  shadow |
| Timmerman | [23] | 2010 | 60Gy/  3Fr  or 54Gy/  3Fr | 55 | NA | 34.4 | NA | 12.7% | 3.6% | 0% |  |  |
| Nagata | [20] | 2010 | 48Gy/  4Fr | 104 | NA | 46.8 | NA | 6.2% | 0% | 0% |  |  |
| Guckenberger | [9] | 2010 | 26Gy/  1Fr  or 37.5Gy/  3Fr | 59 | 33 | 13 | 18.6% | 0% | 0% | 0% | MLD | V2.5-50 |
| Ong | [28] | 2010 | 55Gy/  5Fr  or  60Gy/  8Fr | 18 | 137 | 12.8 | 27.8% | 11.1% | 0% | 0% | V5 |  |
| Grills | [35] | 2010 | 48Gy/  4Fr  or 60Gy/  5Fr | 58 | NA | 30 | 11% | 2% | 0% | 0% |  |  |
| Stauder | [30] | 2011 | 32-60Gy/3-5Fr | 74 | 42.9 | 15.8 | 12.5% | 2.3% | 0% | 1.1% | Max dose |  |
| Matsuo | [53] | 2012 | 48Gy/  4Fr | 74 | 32.5 | 31.4 | 20.3% | 1.4% | 0% | 0% | V25 | PTV volume |
| Barriger | [29] | 2012 | 24-66Gy/3-5Fr | 84 | 48.3 | 17 | 9.4% | 2% | 0.4% | 0% | MLD (4Gy) | V20 (4%) |
| Baker | [37] | 2013 | Multiple | 240 | 37.6 | 15.6 | 11% | 1.1% | 0% | 0% | MLD (6Gy) | V20 (10%) |